Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2024-03-05 Director's Dealing
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2024-03-05 English
PRIMARY DOCUMENT
Director's Dealing
2024-02-28 English
PRIMARY DOCUMENT
Director's Dealing
2024-02-28 English
PRIMARY DOCUMENT
Director's Dealing
2024-02-28 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by uniQure N.V. The Form S-8 is used to register securities to be offered under employee benefit plans, specifically here for the 2014 Share Incentive Plan. The document includes details about the registration of additional shares for issuance under the plan, references to previous registration statements, and exhibits such as legal opinions and consents. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to share registration for employee compensation plans. Therefore, it fits best under the category of Regulatory Filings (RNS), as it is a compliance document filed with the SEC that does not fall into other specific categories like capital changes or proxy statements.
2024-02-28 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 28, 2024, by uniQure N.V. It announces the issuance of a press release containing financial results for the quarter and full year ended December 31, 2023. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, and the document itself does not contain detailed financial statements or substantive financial data. The length of the document is 3866 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain the full financial report or detailed financial data itself.
2024-02-28 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.